An International Study to Evaluate the effectiveness of continuing treatment of enzalutamide after PSA Progression in Patients who have not yet received chemotherapy To determine the efficacy of combination treatment with continued enzalutamide plus abiraterone acetate (abiraterone) and prednisone (or prednisolone) compared with placebo plus abiraterone and predni...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease(Protocol DIM20EXT) • To evaluate the long-term safety of dimebon (latrepirdine) in Huntington disease (HD) subjects who have successfully completed 26 weeks of blinded treatment in the HORIZON protocol (DIM20).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

CONNECTION PLUS: An Open-Label Extension of the CONNECTION Protocol (DIM14) Evaluating Oral Dimebon in Patients with Alzheimer’s Disease To evaluate the long-term safety and tolerability of Dimebon in Alzheimer’s Disease (AD) patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION protocol (DIM14).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

CONNECTION: A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients with Mild-to-Moderate Alzheimer’s Disease • To determine the benefit of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS-cog); and • To determin...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An international study to evaluate the effectiveness of Talazoparib in men with a genomic defect and metastatic castration-resistant prostate cancer who received previous chemotherapy and progressed on hormonal treatment To evaluate efficacy, as measured by best objective response rate (ORR)

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open label study to provide extended treatment in patients treated with Talazoparib To offer extended open label treatment to patients treated with talazoparib in qualifying studies To obtain additional safety data on talazoparib use

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A MULTI-CENTER, PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON’S DISEASE To assess the safety and tolerability of Dimebon, 20 mg three times a day (TID), during 90 days of treatment in subjects with Huntington’s disease (HD).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multinational Study to Evaluate the Safety and Activity of Enzalutamide in Combination With Exemestane in Women With Hormone-Positive Breast Cancer That Is Normal for HER-2 To determine the benefit of exemestane plus enzalutamide versus exemestane plus placebo as assessed by progression free survival (PFS) in patients with advanced breast cancer that is estrogen and/or p...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multinational Study to Evaluate the Safety and Activity of Enzalutamide in Women Whose Breast Cancer Expresses the Androgen Receptor but Does Not Express Estrogen or Progesterone Receptors, and is Not Amplified for the Epidermal Growth Factor Receptor, HER2 Un ensayo multinacional para evaluar la seguridad y la actividad de Enzalutamida en mujeres con cáncer que expresa el receptor de andrógenos pero no los receptores de estrógenos o progesterona, y no está amplificado por el receptor del factor de crecimiento epidérmico HER2 The primary objective is to determine clinical benefit rate in patients with AR+ triple-negative breast cancer (TNBC). El objetivo principal es determinar la tasa de beneficio clínico en pacient...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multinational study to evaluate the safety and effectiveness of enzalutamide in patients whose prostate cancer has not metastasized To determine the efficacy of enzalutamide compared with placebo as assessed by metastasis free survival (MFS).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune